Latest developments in cellular and gene therapies

Published: 10-Mar-2017
Regulatory

Although numerous cellular and gene therapy products are currently in different phases of clinical trials, only 14 have been approved for use by FDA to date

You need to be a subscriber to read this article.
Click here to find out more.

Global market outlooks predict that the autologous cell therapy market will jump from $3.8 billion in 2015 to $23.7 billion in 2024. The stem cell therapy market, which utilises both autologous and allogeneic cell therapies, is expected to reach $170.1 billion by 2020.

The next few years will undoubtedly shift the pharmaceutical paradigm as therapeutics move from mass-produced to patient-specific.

How cellular and gene therapies work

Roughly speaking, cellular and gene therapy products differ from conventional therapeutics in that they harness the body’s natural bioprocesses instead of relying on foreign compounds.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Thats Nice
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Media

Expanding trial data demands new analytical methods

Read more
With research methods and new technologies focused on acquiring individual information from clinical trial participants, the qualitative and quantitative volume of collectable data is growing at an accelerating rate

Trending Articles

  1. Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license The licensing deal with Chiome enhances its open innovation platform
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  4. Are you ready for EP compliance for handheld Raman spectrometers? Thermo Fisher Scientific has adjusted all validation procedures and acceptance criteria for initial instrument calibration as well as annual calibration re-certifications
  5. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Media

Expanding trial data demands new analytical methods

With research methods and new technologies focused on acquiring individual information from clinical trial participants, the qualitative and quantitative volume of collectable data is growing at an accelerating rate
Regulatory

Accelerating and enhancing toxicology assessments

Infographic guides users through ToxHQ’s speedy assessment features
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain

With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
Regulatory

Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license

The licensing deal with Chiome enhances its open innovation platform
Manufacturing

Solvent recycler SPR-200 boosts sustainability in pharma labs

Recycling up to 90% of solvent in isocratic HPLC improves lab efficiency and sustainability
Subscribe now